Prana loss rises to $10m, as R&D spend increases
26 August, 2004 by Graeme O'NeillMelbourne brain-disease drug-discovery company Prana Biotechnology (ASX:PBT, NASDAQ:PRAN) has reported an after-tax loss of $9.9 million in the year to June.
Ambri’s SensiDx still on trial
26 August, 2004 by Graeme O'NeillSydney’s Ambri Technology (ASX:ABI) has announced a net operating loss of $11.4 million for 2004, 35 per cent below last year’s loss of $17.6 million. The company also said earlier this week that its SensiDx ion-channel pregnancy test sensor had yet to meet the full requirements of a commercial viability trial (CVT) in a clinical setting.
Chemgenex rings in $5m loss
26 August, 2004 by Melissa TrudingerChemGenex Pharmaceuticals (ASX: CXS) reported an AUD$5.1 million loss for the 2003-2004, with around $2 million of the loss attributable to costs associated with the merger between Australian company AGT Biosciences and US company ChemGenex Therapeutics in late June.
Solbec expands devil's apple clinical trial
25 August, 2004 by Renate KrellePerth biotech Solbec Pharmaceuticals (ASX:SPB) has expanded the Phase IIb clinical trial for its devil’s apple extract SBP002 – which is already showing promise as a treatment for mesothelioma -- and is commencing clinical trial identification studies against other forms of cancer.
Imugene and CSIRO start efficacy trial of bird flu vaccine
25 August, 2004 by Melissa TrudingerAs reports emerge of a new avian influenza outbreak in Malaysia and rumours that pigs in China are now being infected with the virus herald a potential pandemic, Imugene (ASX: IMU) and CSIRO Livestock Industries have announced they will start an efficacy trial in coming weeks to evaluate their new avian influenza vaccine in chickens.
Proteome Systems' IPO opens
24 August, 2004 by Graeme O'NeillAustralian investors can now buy a piece of North Ryde-based biotechnology company Proteome Systems, the Australian company credited with pioneering the latter-day boom science of proteomics.
Alchemia in good shape
24 August, 2004 by Melissa TrudingerAlchemia (ASX:ACL) has ended the 2003-04 financial year with a $6.5 million loss, slightly less than the recorded loss for the previous period.
GroPep posts $1m profit
24 August, 2004 by Melissa TrudingerGroPep (ASX:GRO) has posted a AUD$1 million profit for the 2003-2004 financial year, achieving its aim of returning to profitability after its disastrous 2002 acquisition of Sydney company Biotech Australia.
Benitec settles another lawsuit
24 August, 2004 by Melissa TrudingerRNAi company Benitec (ASX:BLT) has settled its second patent infringement lawsuit in two weeks, giving US company Genscript Corporation a non-exclusive worldwide licence to manufacture and sell DNA-directed RNAi (ddRNAi) products.
In brief: Burns joins Progen; Cryptome appoints CSO
23 August, 2004 by Renate KrelleProgen Industries (ASX: PGL, NASDAQ: PGLAF), announced today it had appointed former Bresagen chief financial officer and company secretary, Linton Burns, as CFO and company secretary.
Bone Medical completes merger with Revenir
23 August, 2004 by Melissa TrudingerUK biotech company Bone Limited has completed its merger with Perth-based listed property management company Revenir (ASX: REV) after a successful capital raising of $2.5 million closed oversubscribed earlier in the month.
Shark antibodies may lead to new diagnostic
23 August, 2004 by Melissa TrudingerThe structure of a novel class of shark antibodies known as immunoglobulin new antibody receptors (IgNARs) isolated from wobbegong sharks (Orectolobus maculatus) has provided some clues to the evolutionary history of antibodies, and may lead to a new tool for detecting a range of human pathogens.
Acrux to deliver a September IPO
20 August, 2004 by Melissa TrudingerDrug delivery company Acrux is preparing for a late September float on the Australian Stock Exchange after filing its prospectus for an AUD$30 million IPO with the Australian Securities and Investment Commission yesterday.
Cash-poor Prima plans for agreements
20 August, 2004 by Melissa TrudingerDespite capital raisings and exercise of options totalling $7.3 million during the year, Prima Biomed (ASX: PRR) is down to a cash balance of $2.8 million after posting a net loss of $4.9 million for the 2003-2004 financial year.
Ventracor posts $16m loss
19 August, 2004 by Melissa TrudingerVentracor (ASX: VCR) yesterday posted an AUD$15.9 million net loss for the 2003-2004 financial year, up 70 per cent from last year's $9.4 million.
